Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company whose news flow centers on its Barostim neuromodulation platform for cardiovascular disease, particularly heart failure. The company regularly issues press releases and investor updates detailing financial performance, operational metrics and developments related to Barostim.
Readers of CVRX news can expect recurring coverage of quarterly and annual financial and operating results, including revenue trends, gross margin, operating expenses, cash and cash equivalents, and the growth of active implanting centers and sales territories in the U.S. and Europe. The company also reports on reimbursement milestones, such as the transition of Barostim procedures to Category I CPT codes and CMS decisions affecting outpatient payment classifications and physician fee levels.
Another key theme in CVRx news is clinical and regulatory progress. The company has highlighted FDA actions such as the Breakthrough Device designation for Barostim and the grant of an Investigational Device Exemption for the BENEFIT-HF trial, a randomized controlled study designed to evaluate Barostim’s impact on outcomes in an expanded heart failure population. Updates on applications to the Centers for Medicare & Medicaid Services for trial coverage and other reimbursement-related developments are also part of the company’s announcements.
CVRx news releases frequently mention participation in major healthcare and investor conferences, where the management team presents the company’s strategy and Barostim-related data to the investment community. For investors and observers following CVRX, this news page provides a centralized view of earnings releases, reimbursement and coding changes, clinical trial plans, financing arrangements, and conference appearances linked to the company’s heart failure therapy platform.
CVRx, a commercial-stage medical device company, announced its inclusion in the Russell 2000® and 3000® Indexes, effective September 20, 2021. This addition, shortly after their IPO, highlights the company's progress in advancing the commercial adoption of Barostim™, a neuromodulation solution for heart failure. CEO Nadim Yared expressed optimism about the increased visibility and awareness for their therapy resulting from this inclusion in widely used Russell indexes, which manage approximately $10.6 trillion in assets.
CVRx reported a 150% increase in revenue for Q2 2021, totaling $3.1 million. U.S. heart failure revenue surged to $2.0 million from $65,000 year-over-year. The company successfully closed its IPO on July 2, 2021, raising $133.3 million. Gross profit rose to $2.2 million, yet gross margin fell to 70.8%. Notably, net loss expanded to $17.7 million, driven by increased expenses related to stock warrants. The company anticipates full-year revenue between $13.3 million and $13.9 million.
CVRx announced its participation in the Canaccord Genuity 41st Annual Growth Conference scheduled for August 12, 2021 at 11:00 am ET. The management team will present via a live audio webcast accessible on the company's investor relations webpage. The presentation will also be archived for 90 days. CVRx focuses on minimally invasive solutions for cardiovascular diseases, notably the Barostim, which is FDA-approved for treating heart failure.
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will release its second quarter financial results on August 4, 2021, after market close. A conference call to discuss the results is scheduled for 5:30 p.m. ET the same day. Participants can join via telephone or listen to a live webcast available on the CVRx investor website. CVRx's Barostim device, which treats heart failure by sending electrical pulses to baroreceptors, has received FDA approval and Breakthrough Device designation.
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced the appointment of Martha Shadan to its Board of Directors. Shadan brings over 30 years of leadership experience in the life sciences sector, having held key positions at various notable firms, including Miach Orthopaedics and Smith & Nephew. She expressed her commitment to advancing CVRx's innovative therapies, particularly the FDA-approved Barostim device for heart failure patients, which aims to enhance cardiovascular health.
CVRx, a medical technology company, successfully priced its initial public offering (IPO) at $18.00 per share, raising approximately $126 million. The IPO allows for an additional 1,050,000 shares underwriters can purchase. CVRx specializes in solutions for heart failure, notably its Barostim Neo™, the first neuromodulation device for heart failure and the first medical device to receive the FDA's Breakthrough Device Designation. Trading under the ticker symbol 'CVRX' began on June 30, 2021, with J.P. Morgan and others serving as underwriters.
CVRx, Inc. has successfully closed its initial public offering (IPO) of 8,050,000 shares of common stock at $18.00 per share, generating approximately $144.9 million in gross proceeds. This includes an additional 1,050,000 shares exercised by underwriters. The stock began trading on Nasdaq under the ticker CVRX on June 30, 2021. The IPO was facilitated by J.P. Morgan, Piper Sandler, and William Blair as joint book-running managers.